Company Quick10K Filing
Barington/Hilco Acquisition
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 2 $23
10-K 2018-06-15 Annual: 2018-03-31
10-K 2018-06-15 Annual: 2017-12-31
10-Q 2017-11-15 Quarter: 2017-09-30
10-Q 2017-08-18 Quarter: 2017-06-30
10-Q 2017-05-15 Quarter: 2017-03-31
10-K 2017-03-31 Annual: 2016-12-31
10-Q 2016-11-14 Quarter: 2016-09-30
10-Q 2016-08-12 Quarter: 2016-06-30
10-Q 2016-05-16 Quarter: 2016-03-31
10-K 2016-03-30 Annual: 2015-12-31
10-Q 2015-11-10 Quarter: 2015-09-30
10-Q 2015-08-06 Quarter: 2015-06-30
10-Q 2015-05-15 Quarter: 2015-03-31
10-K 2015-05-06 Annual: 2014-12-31
8-K 2018-10-31 Other Events
8-K 2018-08-23 Exhibits
8-K 2018-07-30 Officers
8-K 2018-06-30 Amend Bylaw, Shareholder Vote, Exhibits
8-K 2018-05-17 Exhibits
8-K 2018-04-18 Leave Agreement, Exhibits
8-K 2018-02-14 Enter Agreement, Exhibits
8-K 2018-01-09 Control, Officers, Exhibits
8-K 2018-01-04 Shareholder Vote, Other Events, Exhibits

Barington/Hilco Acquisition Financials

BHAC Metrics, Comps, Filings

Annual | Quarterly

Business

NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

Barington/Hilco Acquisition Corp. (the “Company”) is a blank check company incorporated in Delaware on July 24, 2014. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination, with one or more businesses or entities (a “Business Combination”).

On December 29, 2017, the Company's stockholders approved an extension of the period of time in which the Company is required to consummate a Business Combination until June 30, 2018 (the “Extension Amendment”). The extension is to be implemented in 30-day increments. The number of shares of common stock presented for redemption in connection with the Extension Amendment was 537,804. On January 3, 2018, the Company distributed $5,635,379, or approximately $10.48 per share, to redeeming stockholders. In addition, the Company agreed to contribute $0.04 per share to the Trust Account for each public share that was not converted in connection with the approval of the Extension Amendment, for each 30-day period, or portion thereof, that is needed by the Company to complete a Business Combination from December 31, 2017 through June 30, 2018 (the “Contribution”). On January 4, 2018 and April 23, 2018, the Company deposited an aggregate of $140,475 into the Trust Account in connection with the Extension Amendment.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Invesco DB G10 Currency Harvest Fund (DBV) 24,290 86.3 1% 24,330 20 0 0 280 281 24,267
Metaurus Equity Component Trust (XDIV) 24,128 7.5 13% 24,486 344 0 0 3,153 3,153 23,662
Nexien BioPharma (NTVA) 24,080 -5.6 -1,384% 311 45 0 0 -4,301 -4,301 23,933
Lifeloc Technologies (LCTC) 23,928 46% 25.1 4% 8,782 2,369 8,513 3,901 378 907 22,783
Sierra Monitor (SRMC) 23,849 78% 32.4 1% 11,778 2,813 17,068 13,240 160 666 21,593
Znergy (ZNRG) 23,572 14% -7.3 -336% 1,025 1,831 1,222 173 -3,443 -3,234 23,566
Draper Oakwood Technology Acquisition (DOTA) 23,547 -218.6 -0% 58,936 53,936 0 0 -160 -108 23,539
BioCardia (BCDA) 23,463 -7% -1.6 -538% 2,716 4,952 489 -33 -14,601 -14,508 22,946
BlackRidge Technology (BRTI) 23,351 95% -1.6 -242% 10,714 18,887 367 349 -25,888 -14,352 23,473
Barington/Hilco Acquisition (BHAC) 23,189 -6.7 -22% 9,481 4,481 0 0 -2,081 -2,081 13,844
Provectus Biopharmaceuticals (PVCT) 23,094 -3.6 -261% 2,718 23,684 0 0 -7,105 -6,028 21,770
Nukkleus (NUKK) 23,049 2% -46.5 -136% 324 1,307 19,200 300 -439 -495 23,040
Astro Aerospace (ASDN) 23,044 -3.0 850,352,200% 0 0 -8,504 -7,751 23,019
Trident Brands (TDNT) 22,618 27% -2.9 -186% 5,394 24,698 2,613 696 -10,055 -7,166 20,964
Cincinnati Bancorp (CNNB) 22,616 2.3 1% 206,334 182,814 0 0 2,248 5,006 11,468
Axovant Sciences (AXON) 22,553 0.2 -104% 101,445 72,093 0 0 -105,234 -96,181 -21,373
Synergy CHC (SNYR) 22,472 63% -22.7 -20% 17,493 11,759 30,201 19,133 -3,536 -1,237 28,038
Hedgepath Pharmaceuticals (HPPI) 22,227 -5.2 -184% 2,132 3,305 0 0 -3,917 -3,917 20,202
CafePress (PRSS) 22,127 40% -4.1 -21% 36,635 7,335 76,314 30,369 -7,780 -3,082 12,657

Balance Sheet ($'000)2015-12-312016-12-312017-12-31
Cash43,647223
Accounts Receivable
Inventory
PP&E
Assets43,89743,95414,850
Accounts Payable
Long-Term Debt
Liabilities8038,9549,850
Stockholders' Equity5,0005,0005,000
Income Statement ($'000)2015-12-312016-12-312017-12-31
Revenue
Cost of Revenue
Gross Profit
R&D
SG&A75
Tax000
Net Income-474-243-2,114
Cash Flow ($'000)2015-12-312016-12-312017-12-31
Cash Operating-369-207-284
Cash Investing-43,643-20029,263
Cash Financing44,147230-28,999